logo-loader
Faron Pharmaceuticals Ltd

Faron Pharma updates on Clevegen development as partner discussions advance

Markku Jalkanen, chief executive of Faron Pharmaceuticals Ltd (LON:FARN), updates Proactive London's Andrew Scott following the release of their 2018 results.

The company's main focus recently has been on Clevegen, its cancer immunotherapy which is currently undergoing a phase I/II study.

Meanwhile a second phase III study is now planned for its Traumakine treatment, subject to approval from regulators and external funding.

Quick facts: Faron Pharmaceuticals Ltd

Price: 130 GBX

Market: AIM
Market Cap: £51.16 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'Immune activation from Clevegen has now been demonstrated' Faron Pharma CEO

Faron Pharmaceuticals Oy's (LON:FARN) Markku Jalkanen caught up with Proactive London's Andrew Scott to discuss the recently released Matins trial update which is assessing the firm's drug Clevegen. He says feedback from the dose escalation study confirmed Clevegen has good tolerability...

5 days ago

RNS

Second Price Monitoring Extn

1 week, 3 days ago

Price Monitoring Extension

1 week, 3 days ago

Matins Trial Update

1 week, 5 days ago

Notice of EGM

2 weeks, 3 days ago

Holdings in Company

3 weeks, 5 days ago

Interim results

4 weeks ago

2 min read